Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hematologic Malignancy Reports
Published in: Current Hematologic Malignancy Reports 2/2013

01-06-2013 | Acute Leukemias (E Feldman, Section Editor)

Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Authors: A. K. Fielding, G. A. Zakout

Published in: Current Hematologic Malignancy Reports | Issue 2/2013

Login to get access

Abstract

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is characterized by expression of oncogenic fusion product BCR-ABL1, resulting from reciprocal translocation between chromosomes 9 and 22 [t(9;22)(q34;q11.2)]. Previously perceived to confer poor outcome with at least 10 % lower chance of remission than standard-risk ALL. With the advent of targeted BCR-ABL specific tyrosine-kinase inhibitors (TKIs), higher remission rates were achieved, thus allowing more patients to proceed with the definitive treatment modality—allogeneic hematopoietic stem cell transplantation (alloHSCT). Prime challenges to treatment of Ph+ ALL include appropriate integration of TKIs into remission induction chemotherapeutic regimes, appropriate understanding and implementation of BCR-ABL monitoring for guiding therapeutic intervention(s), and minimizing transplant-related toxicities.
Literature
1.
Moorman A, Harrison C, Buck G, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 Trial. Blood. 2007;109:3189–97.PubMedCrossRef
2.
• Moorman A, Chilton L, Wilkinson J, et al. A population based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2010;115:206–14. This study presents a descriptive account on the demographic, clinical and cytogenetic features of ALL in adults and highlights the rising incidence of the Ph+ cytogenetic anomaly in this age group, which carries one of the worst prognoses.PubMedCrossRef
3.
Burmeister T, Schwartz S, Bartram C, et al. Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. Blood. 2008;112:918–9.PubMedCrossRef
4.
Dombert H, Gabert J, Boiron J, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia—results of the prospective multicenter LALA-94 trial. Blood. 2002;100:2357–66.CrossRef
5.
Gleissner B, Gökbuget N, Bartram C, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood. 2002;99:1536–43.PubMedCrossRef
6.
Faderl S, Kantarjian H, Thomas D, et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma. 2000;36:263–7.PubMedCrossRef
7.
Preti H, O’Brien S, Giralt S, et al. Philadelphia chromosome-positive adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis in 41 patients. Am J Med. 1994;97:60–5.PubMedCrossRef
8.
Secker-Walker L, Craig J, Hawkins J, et al. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia. 1991;5:196–9.PubMed
9.
Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12:7374–9.PubMedCrossRef
10.
Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002;99:3472–5.PubMedCrossRef
11.
Pfeifer H, Wassmann B, Pavlova A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2007;110:727–34.PubMedCrossRef
12.
Mullighan C, Miller C, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453:110–4.PubMedCrossRef
13.
• Matinelli G, Iacobucci I, Storlazzi C, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol. 2009;27:5202–7. This paper highlighted the negative prognostic impact of IKAROS and provided a molecular insight into the aggressive nature of Ph+ ALL.CrossRef
14.
Mullighan C, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470–80.PubMedCrossRef
15.
Iacobucci I, Lonetti A, Messa F, et al. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood. 2008;112:3847–55.PubMedCrossRef
16.
Pfeifer H, Spinelli O, Cayuela J, et al. International standardization of minimal residual disease assessment for Philadelphia chromosome positive acute lymphoblastic leukemia expressing minor-BCR-ABL: updated results of EuroMRD. [Abstract]. Haemtologica. 2012;97(s1):Abstract 0614.
17.
Pfeifer H, Cazzaniga G, Spinelli O, et al. International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Expressing m-BCR-ABL Transcripts: updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL Consortia. [Abstract]. Blood. 2011;118:2535.
18.
Soverini S, Vitale A, Poerio A, et al. Philadelphia positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica. 2011;96:552–7.PubMedCrossRef
19.
Rowe J, Buck G, Burnett A, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG2993. Blood. 2005;106:3760–7.PubMedCrossRef
20.
Thomas D, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103:4396–407.PubMedCrossRef
21.
Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24:460–6.PubMedCrossRef
22.
Thomas D, O’Brien S, Faderl S, et al. Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL) [abstract]. J Clin Oncol 2010; 28:Abstract 6506.
23.
Wassman B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2006;108:1469–77.CrossRef
24.
De Labarthe, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. 2007;109:1408–13.PubMedCrossRef
25.
Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109:3676–8.PubMedCrossRef
26.
Ribera JM, Oriol A, Gonzalez M, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica. 2010;95:87–95.PubMedCrossRef
27.
Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of the phase 2 study. Blood. 2007;110:2309–15.PubMedCrossRef
28.
Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116:2070–7.PubMedCrossRef
29.
Foà R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521–8.PubMedCrossRef
30.
Fielding AK, Buck G, Lazarus H, et al. Imatinib significantly enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukaemia; final results of the UKALLXII/ECOG2993 Trial [Abstract]. Blood. 2010;116:493.CrossRef
31.
Chalandon Y, Thomas X, Hayette S, et al. First results of the GRAAPH-2005 study in younger adult patients with de novo Philadelphia positive acute lymphoblastic leukemia [Abstract]. Blood. 2008;112:12.
32.
Chalandon Y, Thomas X, Hayette S, et al. Is less chemotherapy detrimental in adults with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) treated with high-dose imatinib? Results of the prospective randomized Graaph-2005 study [Abstract]. ASH abstract 2012; Abstract no. 138
33.
Ottmann O, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Cancer. 2007;109:2068–76.PubMedCrossRef
34.
Wassmann B, Gökbuget N, Scheuring U, et al. A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) (CSTI571ADE 10). Ann Hematol. 2003;82:716–20.PubMedCrossRef
35.
Delannoy A, Delabesse E, Lheritier V, et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia. 2006;20:1526–32.PubMedCrossRef
36.
Gruber F, Mustjoki S, Porkka K. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol. 2009;145:581–97.PubMedCrossRef
37.
Bassan R, Rossi G, Pogliani E, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010;28:3644–52.PubMedCrossRef
38.
O’Hare T, Walters D, Stoffregen E, et al. In vitro activity of Bcr-Abl inhibitos AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500–5.PubMedCrossRef
39.
Shah N, Tran C, Lee F, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399–401.PubMedCrossRef
40.
Talpaz M, Shah N, Kartarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531–41.PubMedCrossRef
41.
Lilly M, Ottmann O, Shah N, et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study. Am J Hematol. 2010;85:164–70.PubMed
42.
Rousselot P, Hayette S, Récher C, et al. Dasatinib (Sprycel®) and low intensity chemotherapy for first-line treatment in elderly patients with de novo Philadelphia positive ALL (EWALL-PH-01): kinetics of response, resistance and prognostic significance [Abstract]. Blood. 2010;116:1204.
43.
Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the blood–brain-barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008;112:1005–12.PubMedCrossRef
44.
Takayama N, Sato N, O’Brien S, et al. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukemia due to poor penetration into cerebrospinal fluid. Br J Haematol. 2002;119:106–8.PubMedCrossRef
45.
Soverini S, Colarossi S, Gnani A, et al. Resistance to dasatinib in Philadelphia-positive leukemia and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica. 2007;92:401–4.PubMedCrossRef
46.
Soverini S, Martinelli G, Colarossi S, et al. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J Clin Oncol. 2006;24:e51–2.PubMedCrossRef
47.
Kim D-Y, Joo Y, Lee J-H, et al. Nilotinib combined with multi-agent chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: Interim results of Korean Adult ALL Working Party phase 2 study. [Abstract]. ASH 2012; Abstract no. 614.
48.
Kantarjian H, Kim D-W, Pinilla-Ibarz J, et al. Efficacy and safety of ponatinib in patients with accelerated phase or blast phase chronic myelois leukemia (AP-CML or BP-CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): 12-month follow-up of the PACE trial. [Abstract]. ASH 2012; Abstract no. 915.
49.
Cortes J, Kim D-W, Pinilla-Ibarz J, et al. Initial findings from the PACE trial: a pivotal phase 2 study of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. [Abstract]. Blood. 2011;118:109.CrossRef
50.
Khoury H, Cortes J, Gambacorti-Passerini C, et al. Activity of bosutinib by baseline and emergent mutation status in Philadelphia chromosome-positive leukemia patients with resistance or intolerance to other tyrosine kinase inhibitors. [Abstract]. Blood. 2011;118:110.
51.
Yanada M, Sugiura I, Takeuchi J, et al. Prospective monitoring of BCR-ABL1transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. Br J Haematol. 2008;143:503–10.PubMed
52.
Forman S, O’Donnell M, Nademanee A, et al. Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 1987;70:587–8.PubMed
53.
Barrett A, Horowitz M, Ash R, et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 1992;79:3067–70.PubMed
54.
Sierra J, Radich J, Hansen J, et al. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 1997;90:1410–4.PubMed
55.
Snyder D, Nademanee A, O’Donnell M, et al. Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia. 1999;13:2053–8.PubMedCrossRef
56.
Dombret H, Gabert J, Boiron J, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 trial. Blood. 2002;100:2357–66.PubMedCrossRef
57.
Esperou H, Boiron J, Cayuela J, et al. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society. Bone Marrow Transplant. 2003;31:909–18.PubMedCrossRef
58.
Yanada M, Naoe T, Iida H, et al. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus host disease. Bone Marrow Transplant. 2005;36:867–72.PubMedCrossRef
59.
Laport G, Alvarnas J, Palmer J, et al. Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood. 2008;112:903–9.PubMedCrossRef
60.
•• Fielding A, Rowe J, Richards S, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the international ALL Trial MRC UKALLXII/ECOG2993. Blood. 2009;113:4489–96. This study included the largest prospective data on Ph+ ALL and was the first to demonstrate that alloHSCT is an indispensible treatment modality in Ph+ ALL, as it confers significantly superior relapse-free survival.PubMedCrossRef
61.
Carpenter P, Snyder D, Flowers M, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood. 2007;109:2791–3.PubMed
62.
Kebriaei P, Saliba R, Rondon G, et al. Long-term follow of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcome. Biol Blood Marrow Transplant. 2012;18:584–92.PubMedCrossRef
63.
Nicolini F, Basak G, Soverini S, et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood. 2011;118:5697–700.PubMedCrossRef
64.
Eefting M, Halkes C, Kersting S, et al. Excellent outcome after T cell depleted allogeneic stem cell transplantation with pre-emptive donor lymphocyte infusion for Philadelphia-positive acute lymphoblastic leukemia in first remission. [Abstract]. Haematologica. 2012;97(s1):Abstract 1172.
65.
Pfeifer H, Goekbuget N, Völp C, et al. Long-term outcome of 335 adult patients receiving different schedules of imatinib and chemotherapy as front-line treatment for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). [Abstract]. Blood. 2010;116:173.
66.
Mizuta S, Matsuo K, Yagasaki F, et al. Pre-transplant imatinib-based therapy improves the outcome of allogeneic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. Leukemia. 2011;25:41–7.PubMedCrossRef
67.
Schultz K, Bowman W, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group Study. J Clin Oncol. 2009;27:5175–81.PubMedCrossRef
68.
Rives S, Estella J, Gómez P, et al. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005. Br J Haematol. 2011;154:600–11.PubMedCrossRef
69.
Burke M, Cao Q, Trotz B, et al. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer. 2009;53:1289–94.PubMedCrossRef
70.
Mohty M, Labopin M, Tabrizzi R, et al. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica. 2008;93:303–6.PubMedCrossRef
71.
Arnold R, Massenkeil G, Bornhauser M, et al. Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia. 2002;16:2423–8.PubMedCrossRef
72.
Martino R, Giralt S, Caballero M, et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. Haematologica. 2003;88:555–60.PubMed
73.
Stein A, O’Donnell M, Snyder D, et al. Reduced-intensity stem cell transplantation for high-risk acute lymphoblastic leukaemia. Biol Blood Marrow Transplant. 2009;15:1407–14.PubMedCrossRef
74.
Bachanova V, Verneris M, DeFor T, et al. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood. 2009;113:2902–5.PubMedCrossRef
75.
Ram R, Storb R, Sandmaier B, et al. Nonmyeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high risk acute lymphoblastic leukemia. Haematologica. 2011;96:1113–20.PubMedCrossRef
76.
Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111:1827–33.PubMedCrossRef
77.
Shin H, Chung J, Co G. Imatinib interim therapy between chemotherapeutic cycles and in vivo purging prior to autologous stem cell transplantation, followed by maintenance therapy is a feasible treatment strategy in Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant. 2005;36:917–8.PubMedCrossRef
78.
Wetzler M, Watson D, Stock W, et al. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation – results of CALGB 10001 (Alliance). [Abstract]. ASH 2012; Abstract no. 816.
79.
Wassmann B, Pfeifer H, Bethge W, et al. Up-front versus minimal residual disease triggered imatinib after stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukaemia: interim results of a randomized phase III GMALL study [Abstract]. Bone Marrow Transplant. 2009;43:S48.
80.
Pfeifer H, Wassmann B, Bethge W, et al. Updated long-term results of a randomized comparison of prophylactic and pre-emptive imatinib following allogeneic stem cell transplantation for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). [Abstract]. Blood. 2011;118(s1):247.
81.
Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002;100:1965–71.PubMedCrossRef
82.
Soverinin S, De Benedittis C, Polakova K, et al. Dissecting the complexity of Philadelphia-positive mutated population by ultra-deep sequencing of the BCR-ABL kinase domain: Biological and clinical implications. [Abstract]. ASH 2012; Abstract no. 692.
83.
Pullarkat V, Slovak M, Kopecky K, et al. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood. 2008;111:2563–72.PubMedCrossRef
84.
Patel B, Rai L, Buck G, et al. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol. 2010;148:80–9.PubMedCrossRef
85.
Soverini S, De Benedittis C, Polakova K, et al. Ultra-deep sequencing of the BCR-ABL kinase domain allows earlier detection and more accurate characterization of resistant subclones in Philadelphia-positive acute lymphoblastic leukemia patients receiving tyrosine kinase inhibitor-based therapies. [Abstract]. ASH 2012; Abstract 284.
86.
Cortes J, Kim D-W, Pinilla-Ibarz J, et al. A pivotal phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 12-month follow-up of the PACE trial. [Abstract]. ASH 2012; Abstract no. 163.
87.
Mortuza F, Papaioannou M, Moreira I, et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol. 2002;20:1094–104.PubMedCrossRef
88.
Preudhomme C, Henic N, Cazin B, et al. Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL). Leukemia. 1997;11:294–8.PubMedCrossRef
89.
Pane F, Cimino G, Izzo B, et al. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia positive acute lymphoblastic leukemia. Leukemia. 2005;19:628–35.PubMed
90.
Lee S, Kim D, Cho B, et al. Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol. 2003;120:145–53.PubMedCrossRef
91.
Leguay T, Witz F, De Botton S, et al. Post-Remission Therapy with Imatinib and HAM Improve MRD before Tansplant for Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): results of the GRAALL AFR03 Study. [Abstract]. Blood. 2006;108:1877.CrossRef
92.
Pfeifer H, Lange T, Wystub S, et al. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. Leukemia. 2012;26:1475–81.PubMedCrossRef
93.
Wassmann B, Pfeifer H, Stadler M, et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2005;106:458–63.PubMedCrossRef
94.
Pfeifer H, Wettner C, Wassmann B, et al. Long term follow up of elderly patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL): updated results of the GMALL elderly trials. [Abstract]. Haematologica. 2012;97(s1):1124.
95.
Pfeifer H, Wettner C, Wassman, et al. Long-term follow-up of 121 elderly patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) treated in prospective GMALL trials supports a greater emphasis on allogeneic SCT as definitive postremission therapy. ASH Abstract 2012; Abstract no. 2608.
96.
Rousselot P, Coudé M, Huguet F, et al. Dasatinib (Sprycel®) and Low intensity chemotherapy for first-line treatment in patients with de novo Philadelphia positive ALL aged 55 and over: final results of the EWALL-Ph-01 Study. [Abstract]. ASH 2012; Abstract no 666.
97.
Pfeifer H, Wystub S, Binkebanck A, et al. Imatinib (IM) and interferon-alpha (IFN-a) maintenance therapy is associated with long-term DFS in a subset of elderly patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). [Abstract]. ASH 2012; Abstract no. 1503.
98.
Chelghoum Y, Vey N, Raffoux E, et al. Acute leukemia during pregnancy: a report on 37 patients and a review of the literature. Cancer. 2005;104:110–7.PubMedCrossRef
99.
Pizzuto J, Aviles A, Noriega L, et al. Treatment of acute leukemia during pregnancy: presentation of nine cases. Cancer Treat Rep. 1980;64:679–83.PubMed
100.
Reynoso EE, Shepherd FA, Messner HA, et al. Acute leukemia during pregnancy: the Toronto Leukemia Study Group experience with long-term follow-up of children exposed in utero to chemotherapeutic agents. J Clin Oncol. 1987;5:1098–106.PubMed
101.
Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004;5:283–91.PubMedCrossRef
102.
Heartin E, Walkinshaw S, Clark R. Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib. Leuk Lymphoma. 2004;45:1307–8.PubMedCrossRef
103.
Ault P, Kantarjian H, O’Brien S, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2006;24:1204–8.PubMedCrossRef
104.
Ali R, Ozkalemkas F, Ozcelik T, et al. Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission. Leuk Res. 2005;29:971–3.PubMedCrossRef
105.
Hensley ML, Ford JM. Imatinib treatment: specifi c issues related to safety, fertility, and pregnancy. Semin Hematol. 2003;40:21–5.PubMedCrossRef
106.
107.
Choudhary DR, Mishra P, Kumar R, et al. Pregnancy on imatinib: fatal outcome with meningocele. Ann Oncol. 2006;17:178–9.PubMedCrossRef
108.
Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109:944–50.PubMedCrossRef
109.
Oriol A, Vives S, Hernandez-Rivas J, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 2010;95:589–96.PubMedCrossRef
110.
Thomas D, Kantarjian H, Smith T, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999;86:1216–30.PubMedCrossRef
111.
Tavernier E, Boiron J, Huguet F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21:1907–14.PubMedCrossRef
112.
Ishida Y, Terasako K, Oshima K, et al. Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation. Int J Hematol. 2010;92:542–6.PubMedCrossRef
113.
Millot F, Cividin M, Brizard F, et al. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009;52:891–2.PubMedCrossRef
114.
Ottmann O, Larson R, Kantarjian H, et al. Nilotinib in patients with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib [Abstract]. Blood. 2007;110:Abstract 2815.CrossRef
115.
Ottmann O, Larson R, Kantarjian H, et al. Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2012. doi:10.​1038/​leu.​2012.​324.
116.
Castillo E, Al-Rajabi R, Pandya D, et al. A pilot study of the combination of nilotinib and hyper-CVAD for Philadelphia chromosome positive acute lymphocytic leukemia and lymphoid blast crisis chronic myelogenous leukemia. Blood. 2010;116:885–6. abstract 2144.
117.
Topp M, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493–8.PubMedCrossRef
118.
Collins R, Goldstein S, Giralt S, et al. Donor leukocyte infusions in acute lymphoblastic leukemia. Bone Marrow Transplant. 2000;26:511–6.PubMedCrossRef
119.
Kolb H, Schattenberg A, Goldman J, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041–50.PubMed
120.
Keil F, Kalhs P, Haas O, et al. Relapse of Philadelphia chromosome positive acute lymphoblastic leukemia after marrow transplantation: sustained molecular remission after early and dose-escalating infusion of donor leucocytes. Br J Haematol. 1997;97:161–4.PubMedCrossRef
121.
Yazaki M, Andoh M, Ito T, et al. Successful prevention of hematological relapse for a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation by donor leukocyte infusion. Bone Marrow Transplant. 1997;19:393–4.PubMedCrossRef
122.
Matsue K, Tabayashi T, Yamada K, et al. Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant. 2002;29:63–6.PubMedCrossRef
Metadata
Title
Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Authors
A. K. Fielding
G. A. Zakout
Publication date
01-06-2013
Publisher
Current Science Inc.
Published in
Current Hematologic Malignancy Reports / Issue 2/2013
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-013-0155-4

Other articles of this Issue 2/2013

Current Hematologic Malignancy Reports 2/2013 Go to the issue

Acute Leukemias (E Feldman, Section Editor)

Developmental Therapeutics in Acute Myelogenous Leukemia: Are There Any New Effective Cytotoxic Chemotherapeutic Agents Out There?

Acute Leukemias (F Ravandi, Section Editor)

Novel Therapeutic Strategies in Adult Acute Lymphoblastic Leukemia – A Focus on Emerging Monoclonal Antibodies

Acute Leukemias (E Feldman, Section Editor)

Strategies to Reduce Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia

Acute Leukemias (E Feldman, Section Editor)

Is Minimal Residual Disease Monitoring Clinically Relevant in Adults with Acute Myelogenous Leukemia?

Acute Leukemias (F Ravandi, Section Editor)

Are Results of Targeted Gene Sequencing Ready to Be Used for Clinical Decision Making for Patients with Acute Myelogenous Leukemia?

Acute Leukemias (E Feldman, Section Editor)

Acute Myeloid Leukemia Following a Myeloproliferative Neoplasm: Clinical Characteristics, Genetic Features and Effects of Therapy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits